Clinical trial
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of Icotinib in Patients With Advanced Cancers
NCT02033148 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of Icotinib in Patients With Advanced Cancers
- Lead sponsor
- Roswell Park Cancer Institute
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- August 31, 2014
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
unspecified adult solid tumor, protocol specific